Sex Differences in Trajectories of LDL Cholesterol Control in Chronic Coronary Syndromes

BACKGROUND AND AIMS: Sex differences in the longitudinal evolution of low-density lipoprotein cholesterol (LDL-C) management among patients with chronic coronary syndromes (CCS) are not well known. METHODS: In the international CLARIFY registry, which included patients with CCS, LDL-C levels were monitored annually over the 5-year follow-up period. The analysis included patients with available LDL-C measurement at baseline. Target LDL-C was set at 100 mg/dL, in line with prevailing recommendations at enrolment. Sex-specific differences in LDL-C were adjusted for age and geographical region. Impact of longitudinal LDL-C was assessed using mean LDL-C up to the primary outcome of interest or last follow-up defined as cardiovascular (CV) death or MI during 5-year follow-up, evaluated using multivariable analysis. RESULTS: Of 32,376 patients in the initial cohort, women were less likely to have LDL-C measurement available at baseline (aOR 1.12, 95%CI 1.06-1.18, p<0.001). Of the 21,925 patients with LDL-C measurement at baseline, 21.6% were women. At inclusion, women were less likely to receive statins (82.7% vs. 85.4%, p<0.001) and more likely to fail reaching the LDL-C target (45.6% vs. 37.4%; aOR 1.47, 95%CI 1.38-1.58, p<0.001). This disparity persisted across the 5-year follow-up (p<0.001 for every year). Overall, women were more likely than men to never reach the target LDL-C during follow-up (20.7% vs. 15.8%; aOR 1.44, 95% CI 1.32-1.56, p<0.001). Higher mean LDL-C during follow-up was associated with an increased risk of the primary outcome (aHR 1.06 per 10 mg/dL increase, 95% CI 1.04-1.07, p<0.001). CONCLUSION: Women with CCS were less likely to have LDL-C measurement available at baseline, to receive lipid-lowering drugs and consistently exhibited poorer LDL-C control than men over the 5-year follow-up. Given the association of LDL-C and adverse CV outcomes, targeted interventions to close the sex gap in secondary prevention are needed.

Authors

Institutions

Publication Details

Journal
European Journal of Preventive Cardiology
Published
2026-08-17
DOI
https://doi.org/10.1093/eurjpc/zwag419
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sex Differences in Trajectories of LDL Cholesterol Control in Chronic Coronary Syndromes

Philippe Gabríel Steg, Gaspard Suc, Ian Ford, Grégory Ducrocq et al.
European Journal of Preventive Cardiology
Lipoproteins and Cardiovascular Health
article

Sex Differences in Trajectories of LDL Cholesterol Control in Chronic Coronary Syndromes

Philippe Gabríel Steg, Gaspard Suc, Ian Ford, Grégory Ducrocq, Jean‐Claude Tardif, Michał Tendera, Jules Mesnier, Louis Giovachini, Roberto Ferrari, Kim M Fox
article en

Abstract

BACKGROUND AND AIMS: Sex differences in the longitudinal evolution of low-density lipoprotein cholesterol (LDL-C) management among patients with chronic coronary syndromes (CCS) are not well known. METHODS: In the international CLARIFY registry, which included patients with CCS, LDL-C levels were monitored annually over the 5-year follow-up period. The analysis included patients with available LDL-C measurement at baseline. Target LDL-C was set at 100 mg/dL, in line with prevailing recommendations at enrolment. Sex-specific differences in LDL-C were adjusted for age and geographical region. Impact of longitudinal LDL-C was assessed using mean LDL-C up to the primary outcome of interest or last follow-up defined as cardiovascular (CV) death or MI during 5-year follow-up, evaluated using multivariable analysis. RESULTS: Of 32,376 patients in the initial cohort, women were less likely to have LDL-C measurement available at baseline (aOR 1.12, 95%CI 1.06-1.18, p<0.001). Of the 21,925 patients with LDL-C measurement at baseline, 21.6% were women. At inclusion, women were less likely to receive statins (82.7% vs. 85.4%, p<0.001) and more likely to fail reaching the LDL-C target (45.6% vs. 37.4%; aOR 1.47, 95%CI 1.38-1.58, p<0.001). This disparity persisted across the 5-year follow-up (p<0.001 for every year). Overall, women were more likely than men to never reach the target LDL-C during follow-up (20.7% vs. 15.8%; aOR 1.44, 95% CI 1.32-1.56, p<0.001). Higher mean LDL-C during follow-up was associated with an increased risk of the primary outcome (aHR 1.06 per 10 mg/dL increase, 95% CI 1.04-1.07, p<0.001). CONCLUSION: Women with CCS were less likely to have LDL-C measurement available at baseline, to receive lipid-lowering drugs and consistently exhibited poorer LDL-C control than men over the 5-year follow-up. Given the association of LDL-C and adverse CV outcomes, targeted interventions to close the sex gap in secondary prevention are needed.

European Journal of Preventive Cardiology
Inserm (FR), Medical University of Silesia (PL), Université Paris Cité (FR), Montreal Heart Institute (CA), Sorbonne Paris Cité (FR), Royal Brompton Hospital (GB), Assistance Publique – Hôpitaux de Paris (FR), Maria Cecilia Hospital (IT), Hôpital Bichat-Claude-Bernard (FR), Alliance nationale pour les sciences de la vie et de la santé (FR)
Gender equality
Openalex Percentile: Top 7%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.